Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors

被引:5
作者
Luo, Ning [1 ]
Li, Hu [1 ]
Luo, Yindeng [2 ]
Hu, Peng [1 ]
Liang, Luwen [1 ]
Zhang, Rong [1 ]
Zhang, Dazhi [1 ]
Cai, Dachuan [1 ]
Kang, Juan [1 ,3 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 2, Inst Viral Hepatitis, Dept Infect Dis,Key Lab Mol Biol Infect Dis,Minist, Chongqing, Peoples R China
[2] Chongqing Med Univ, Affiliated Hosp 2, Dept Radiol, Chongqing, Peoples R China
[3] Chongqing Med Univ, Affiliated Hosp 2, Inst Viral Hepatitis, Dept Infect Dis,Key Lab Mol Biol Infect Dis,Minist, 288 Tianwen Ave, Chongqing 401336, Peoples R China
关键词
Psoas muscle index; hepatocellular carcinoma; immune checkpoint inhibitors; tyrosine kinase inhibitors; nutrition; BODY-MASS INDEX; NUTRITIONAL RISK INDEX; TRANSARTERIAL CHEMOEMBOLIZATION; LENVATINIB TREATMENT; PLUS BEVACIZUMAB; LIVER-CANCER; OPEN-LABEL; PHASE-III; OUTCOMES; RECURRENCE;
D O I
10.1080/21645515.2023.2258567
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Currently, the relationship between nutritional indices and the prognosis of hepatocellular carcinoma (HCC) patients treated with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) remains unclear. This study aims to investigate the prognostic value of psoas muscle index (PMI), prognostic nutritional index (PNI), body mass index (BMI), and geriatric nutritional risk index (GNRI) in HCC patients treated with ICIs combined with TKIs. A total of 124 male patients with HCC were included in this study. PNI, PMI, BMI, and GNRI were calculated at the beginning of treatment. The Cox proportional hazards model was used to analyze the effect of various variables. In the univariate analysis, PMI, PNI, GNRI, and ALB were found to impact the outcomes of the patients at different follow-up times. However, the predictive value of these nutritional indices was eliminated when established risk factors were considered. In the multivariate analysis that only included nutrition-related indicators, PMI emerged as an independent prognostic factor for 1-year treatment outcomes. The group with low PMI (& LE;5.5409 cm2/m2) was found to have a higher risk of death at one year and at the end of the follow-up period.
引用
收藏
页数:11
相关论文
共 65 条
[1]   Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients [J].
Akiyama, Takumi ;
Mizuta, Toshihiko ;
Kawazoe, Seiji ;
Eguchi, Yuichiro ;
Kawaguchi, Yasunori ;
Takahashi, Hirokazu ;
Ozaki, Iwata ;
Fujimoto, Kazuma .
WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (07) :914-921
[2]   The Role of Inflammation in Liver Cancer [J].
Bishayee, Anupam .
INFLAMMATION AND CANCER, 2014, 816 :401-435
[3]   Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients [J].
Bouillanne, O ;
Morineau, G ;
Dupont, C ;
Coulombel, I ;
Vincent, JP ;
Nicolis, I ;
Benazeth, S ;
Cynober, L ;
Aussel, C .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2005, 82 (04) :777-783
[4]   Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study [J].
Cai, Liang ;
Li, Honglu ;
Guo, Jiang ;
Zhao, Wenpeng ;
Duan, Youjia ;
Hou, Xiaopu ;
Cheng, Long ;
Du, Hongliu ;
Shao, Xihong ;
Diao, Zhenying ;
Li, Changqing .
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2021, 45 (04)
[5]   The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib [J].
Caputo, Francesco ;
Dadduzio, Vincenzo ;
Tovoli, Francesco ;
Bertolini, Giulia ;
Cabibbo, Giuseppe ;
Cerma, Krisida ;
Vivaldi, Caterina ;
Faloppi, Luca ;
Rizzato, Mario Domenico ;
Piscaglia, Fabio ;
Celsa, Ciro ;
Fornaro, Lorenzo ;
Marisi, Giorgia ;
Conti, Fabio ;
Silvestris, Nicola ;
Silletta, Marianna ;
Lonardi, Sara ;
Granito, Alessandro ;
Stornello, Caterina ;
Massa, Valentina ;
Astara, Giorgio ;
Delcuratolo, Sabina ;
Cascinu, Stefano ;
Scartozzi, Mario ;
Casadei-Gardini, Andrea .
PLOS ONE, 2020, 15 (05)
[6]   Circulating tumor cell associated white blood cell cluster as a biomarker for metastasis and recurrence in hepatocellular carcinoma [J].
Chen, Jing ;
Luo, Yuhong ;
Xi, Xiaoxue ;
Li, Haixia ;
Li, Shufen ;
Zheng, Lei ;
Yang, Dinghua ;
Cai, Zhen .
FRONTIERS IN ONCOLOGY, 2022, 12
[7]   Prognostic factors after resection for hepatocellular carcinoma in noncirrhotic livers: Univariate and multivariate analysis [J].
Chen, MF ;
Tsai, HP ;
Jeng, LB ;
Lee, WC ;
Yeh, CN ;
Yu, MC ;
Hung, CM .
WORLD JOURNAL OF SURGERY, 2003, 27 (04) :443-447
[8]   Prognostic Nutritional Index and Neutrophil/Lymphocyte Ratio Can Serve as Independent Predictors of the Prognosis of Hepatocellular Carcinoma Patients Receiving Targeted Therapy [J].
Chen, Wei ;
Zhang, Mingjun ;
Chen, Chanjuan ;
Pang, Xiaonan .
JOURNAL OF ONCOLOGY, 2022, 2022
[9]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[10]   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502